Specialist pharmaceutical outsourcing services provider PCI Pharma Services has announced the appointment of Robert Gibbs to its Laboratory Services team.
With nearly 20 years' experience working in the science and pharmaceutical sectors, Gibbs joins PCI as a Business Development Manager and will be responsible for growing the laboratory services segment of the business, with a key focus on packaging services for PCI’s Hay-on-Wye, UK and Dublin, EU sites.
Having started his career as a laboratory assistant, Gibbs quickly found his way into analytics and quality control before moving into commercial packaging, taking responsibility for quality control inspections and regulatory audits for the MHRA and FDA. Most recently, he was responsible for integrating teams of scientists into pharmaceutical laboratories.
Colin White, Managing Director, Hay-on-Wye at PCI, said: “Having had an extensive career, with first-hand experience of working in a quality-controlled laboratory, Robert is the perfect person to support our clients as they look for expertise in analytical development and testing.”
“Effective analytical methodologies and analysis can be pivotal to the success of a drug and in advancing commercialisation. I am very much looking forward to working with him closely to support our expanding client base.”
Gibbs said: “I am looking forward to continuing the expansion of the service offered by PCI and raising awareness of our profile to current and prospective clients in the UK, throughout Europe, as well as our extensive client base in the US. I also hope to be actively involved in the establishment of the EU based laboratory testing facility to ensure PCI can continue to provide seamless EU importation testing and Qualified Person release services for our clients.”
Gibbs has joined the team at PCI's Hay-on-Wye facility in Wales, one of the company's four locations in the UK and complementing its Dublin, Ireland site.
In early 2017, PCI announced a programme of significant investment in the expansion of its serialisation capabilities, increasing serialisation capacity across its facilities in both the US and EU to support clients in advance of meeting both US DSCSA and EU FMD implementation dates. The creation of this role further complements PCIs serialisation strategy across Europe, providing a suite of services to support commercialisation of lifesaving medicines.
